JP2012521786A - インフルエンザウイルスワクチン及びその使用 - Google Patents

インフルエンザウイルスワクチン及びその使用 Download PDF

Info

Publication number
JP2012521786A
JP2012521786A JP2012503612A JP2012503612A JP2012521786A JP 2012521786 A JP2012521786 A JP 2012521786A JP 2012503612 A JP2012503612 A JP 2012503612A JP 2012503612 A JP2012503612 A JP 2012503612A JP 2012521786 A JP2012521786 A JP 2012521786A
Authority
JP
Japan
Prior art keywords
influenza
seq
virus
polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012503612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012521786A5 (cg-RX-API-DMAC7.html
Inventor
シー． ロウエン アニセ
ステエル ジョフン
ガルシアサストレ アドルフォ
パレセ ペテル
Original Assignee
モウント シナイ スクール オフ メディシネ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モウント シナイ スクール オフ メディシネ filed Critical モウント シナイ スクール オフ メディシネ
Publication of JP2012521786A publication Critical patent/JP2012521786A/ja
Publication of JP2012521786A5 publication Critical patent/JP2012521786A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012503612A 2009-03-30 2010-03-30 インフルエンザウイルスワクチン及びその使用 Withdrawn JP2012521786A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16489609P 2009-03-30 2009-03-30
US61/164,896 2009-03-30
US29908410P 2010-01-28 2010-01-28
US61/299,084 2010-01-28
PCT/US2010/029202 WO2010117786A1 (en) 2009-03-30 2010-03-30 Influenza virus vaccines and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016113966A Division JP2016199557A (ja) 2009-03-30 2016-06-08 インフルエンザウイルスワクチン及びその使用

Publications (2)

Publication Number Publication Date
JP2012521786A true JP2012521786A (ja) 2012-09-20
JP2012521786A5 JP2012521786A5 (cg-RX-API-DMAC7.html) 2013-05-16

Family

ID=42359461

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012503612A Withdrawn JP2012521786A (ja) 2009-03-30 2010-03-30 インフルエンザウイルスワクチン及びその使用
JP2016113966A Withdrawn JP2016199557A (ja) 2009-03-30 2016-06-08 インフルエンザウイルスワクチン及びその使用
JP2018089627A Pending JP2018134107A (ja) 2009-03-30 2018-05-08 インフルエンザウイルスワクチン及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016113966A Withdrawn JP2016199557A (ja) 2009-03-30 2016-06-08 インフルエンザウイルスワクチン及びその使用
JP2018089627A Pending JP2018134107A (ja) 2009-03-30 2018-05-08 インフルエンザウイルスワクチン及びその使用

Country Status (6)

Country Link
US (2) US9051359B2 (cg-RX-API-DMAC7.html)
EP (2) EP2413962A1 (cg-RX-API-DMAC7.html)
JP (3) JP2012521786A (cg-RX-API-DMAC7.html)
AU (2) AU2010234849B2 (cg-RX-API-DMAC7.html)
CA (1) CA2787099A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010117786A1 (cg-RX-API-DMAC7.html)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013526849A (ja) * 2010-03-30 2013-06-27 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
JP2016508133A (ja) * 2012-12-18 2016-03-17 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
JP2016531590A (ja) * 2013-09-18 2016-10-13 レヴィセプト エルティーディーＬｅｖｉｃｅｐｔ Ｌｔｄ 融合タンパク質
JP2016199557A (ja) * 2009-03-30 2016-12-01 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
JP2017527303A (ja) * 2014-07-17 2017-09-21 レヴィセプト リミテッド Ｐ７５ｎｔｒニューロトロフィン結合タンパク質の治療的使用
JP2019516374A (ja) * 2016-05-19 2019-06-20 クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン がんの腫瘍崩壊療法のためのｖｓｖ／ｎｄｖハイブリッドウイルス
US10544207B2 (en) 2013-03-14 2020-01-28 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
JPWO2019124557A1 (ja) * 2017-12-21 2021-01-28 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
US11266734B2 (en) 2016-06-15 2022-03-08 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
WO2022071492A1 (ja) * 2020-09-30 2022-04-07 キリンホールディングス株式会社 インフルエンザウイルス抑制用の融合タンパク質およびこれを含む医薬組成物
JP2023539771A (ja) * 2020-09-07 2023-09-19 インターベット インターナショナル ベー． フェー． Ｈａ抗体陽性ターゲットのためのｈａステムワクチン
US12364746B2 (en) 2018-06-21 2025-07-22 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101540822B1 (ko) 2007-03-27 2015-07-30 씨 레인 바이오테크놀로지스, 엘엘씨 항체 대용물 경쇄 서열을 포함하는 구축물 및 라이브러리
NZ587108A (en) 2007-11-27 2013-04-26 Medicago Inc Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
CN102046656A (zh) * 2008-03-28 2011-05-04 航道生物技术有限责任公司 针对病毒抗原的中和性分子
EP2430047B1 (en) 2009-05-13 2018-03-28 i2 Pharmaceuticals, Inc. Neutralizing molecules to influenza viruses
CA2800182A1 (en) 2009-05-26 2010-12-02 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
JP2013520167A (ja) 2010-02-18 2013-06-06 テクノヴァックス，インコーポレイテッド 万能ウイルス様粒子（ｖｌｐ）インフルエンザワクチン
WO2011103453A2 (en) * 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
AU2011261396B2 (en) 2010-06-02 2015-11-05 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
US9060972B2 (en) * 2010-10-30 2015-06-23 George Dacai Liu Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
US9463237B2 (en) * 2011-01-31 2016-10-11 Baxalta Incorporated Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses
ES2841899T3 (es) 2011-07-18 2021-07-12 Inst Res Biomedicine Anticuerpos neutralizantes del virus de la influenza A y usos de los mismos
US10300140B2 (en) 2011-07-28 2019-05-28 I2 Pharmaceuticals, Inc. Sur-binding proteins against ERBB3
WO2013020074A2 (en) * 2011-08-03 2013-02-07 Children's Medical Center Corporation A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
EP2758075B1 (en) 2011-09-20 2023-05-03 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
CA2849822C (en) 2011-09-23 2021-05-11 Gary J. Nabel, M.D. Novel influenza hemagglutinin protein-based vaccines
IN2014CN03077A (cg-RX-API-DMAC7.html) 2011-09-30 2015-07-03 Medicago Inc
JP6294828B2 (ja) * 2011-11-28 2018-03-14 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． インフルエンザウイルスワクチンおよびその使用
ES2710916T3 (es) 2011-12-22 2019-04-29 I2 Pharmaceuticals Inc Proteínas de unión sustitutas
US20130315955A1 (en) * 2012-04-13 2013-11-28 Protein Sciences Corporation Stability and potency of hemagglutinin
US9550813B2 (en) 2012-05-22 2017-01-24 The Board Of Trustees Of The Leland Stanford Junior University Disulfide stabilized foldon polypeptides
WO2013177444A2 (en) * 2012-05-23 2013-11-28 The Board Of Trustees Of The Leland Stanford Junior University Influenza vaccine constructs
RU2545695C2 (ru) * 2012-07-17 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт экспериментальной медицины" Северо-Западного отделения Российской академии медицинских наук (ФГБУ "НИИЭМ" СЗО РАМН) Вакцинный штамм вируса гриппа в/60/висконсин/2010/125
RU2531235C2 (ru) * 2013-02-15 2014-10-20 Общество с ограниченной ответственностью "Универсальные БиоСистемы" (ООО "УБС") Поливалентная вакцина против гриппа на основе гибридного белка
US9649375B2 (en) 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
US12467058B2 (en) 2013-03-28 2025-11-11 Aramis Biotechnologies Inc. Influenza virus-like particle production in plants
AU2014245779B2 (en) * 2013-03-28 2020-02-06 Aramis Biotechnologies Inc. Influenza virus-like particle production in plants
MY190097A (en) * 2013-05-30 2022-03-28 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
US20160258005A1 (en) * 2013-07-02 2016-09-08 The Trustees Of The University Of Pennsylvania Methods for rapid ribonucleic acid fluorescence in situ hybridization
EP3805254A1 (en) 2013-08-03 2021-04-14 Calder Biosciences Inc. Methods of making and using influenza virus hemagglutinin complexes
WO2015054639A1 (en) 2013-10-11 2015-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus vaccines
DK3092309T3 (da) 2014-01-10 2021-04-12 Medicago Inc Cpmv-forstærkerelementer
EP3137487B1 (en) * 2014-05-01 2021-03-03 Indian Institute of Science Polypeptides for generating anti-influenza antibodies and uses thereof
BR112016030577A8 (pt) * 2014-07-10 2021-07-20 Janssen Vaccines & Prevention Bv polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, composição e usos destes
CN106661091B (zh) 2014-07-10 2020-10-30 扬森疫苗与预防公司 流行性感冒病毒疫苗及其用途
AU2015373928B2 (en) 2014-12-31 2019-10-17 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Novel multivalent nanoparticle-based vaccines
US10799575B2 (en) 2015-06-25 2020-10-13 Technovax, Inc. Flavivirus and alphavirus virus-like particles (VLPS)
US10022436B2 (en) * 2016-01-11 2018-07-17 Verndari, Inc. Microneedle compositions and methods of using same
WO2018013704A1 (en) 2016-07-12 2018-01-18 Duke University Engineered influenza polynucleotides, viruses, vaccines and methods of making and using the same
KR20240042570A (ko) 2016-09-02 2024-04-02 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도
US20190314486A1 (en) * 2016-10-21 2019-10-17 Merck Sharp & Dohme Corp. Influenza hemagglutinin protein vaccines
US11111277B2 (en) 2016-12-28 2021-09-07 Invvax, Inc. Influenza vaccines
AU2018319501A1 (en) 2017-08-21 2020-04-02 Dyadic International Inc. Production of flu vaccine in Myceliophthora thermophila
EP3664839A4 (en) 2017-10-04 2021-10-20 Georgia State University Research Foundation, Inc. HEADLESS HEMAGGLUTININ INFLUENZA Vaccine
EP3713600A4 (en) * 2017-11-22 2021-08-11 Her Majesty The Queen In Right of Canada as represented by The Minister of Health SYNTHETIC HEMAGGLUTININ AS A UNIVERSAL VACCINE AGAINST INFECTION BY TYPE B INFLUENZA VIRUSES (IBV)
BR112020014343A2 (pt) 2018-01-23 2020-12-08 Janssen Vaccines & Prevention B.V. Vacinas contra o vírus da influenza e seus usos
JP6622825B2 (ja) * 2018-01-25 2019-12-18 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Ａ型インフルエンザウイルス中和抗体及びその使用法
US11690907B2 (en) 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US11696948B2 (en) 2018-06-12 2023-07-11 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US11529413B2 (en) 2018-06-12 2022-12-20 Kbio Holdings Limited Virus and antigen purification and conjugation
BR112020025250A2 (pt) 2018-06-12 2021-03-09 Kentucky Bioprocessing, Inc. Purificação e conjugação de vírus e antígeno
KR20210052389A (ko) 2018-08-27 2021-05-10 리제너론 파마슈티칼스 인코포레이티드 다운스트림 정제에서의 라만 분광법의 사용
WO2020163768A1 (en) 2019-02-07 2020-08-13 Duke University Stabilized 9 and 10 segmented influenza viruses as a vaccine platform and methods of making and using same
WO2020245722A1 (en) 2019-06-02 2020-12-10 Pentavalent Bio Sciences Pvt Ltd Live attenuated universal influenza virus vaccines, methods and uses thereof
JP2020048568A (ja) * 2019-11-22 2020-04-02 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Ａ型インフルエンザウイルス中和抗体及びその使用法
WO2021216103A1 (en) * 2020-04-20 2021-10-28 Mahna Satish Controlled exposure to pathogens for generating immunity
WO2022020460A1 (en) * 2020-07-21 2022-01-27 Flugen, Inc. Vaccine using m2/bm2-deficient influenza vectors
US20230390383A1 (en) * 2020-10-20 2023-12-07 Duke University Replication incompetent influenza vaccine platform for foreign protein delivery
AU2022425707A1 (en) * 2021-12-31 2024-07-04 Mynvax Private Limited Polypeptide fragments, immunogenic composition against influenza virus, and implementations thereof

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
ZA836080B (en) 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
US5106619A (en) 1983-12-20 1992-04-21 Diamond Scientific Co. Preparation of inactivated viral vaccines
US4693981A (en) 1983-12-20 1987-09-15 Advanced Genetics Research Institute Preparation of inactivated viral vaccines
FR2583429B1 (fr) 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
US5182192A (en) 1987-03-27 1993-01-26 The Wistar Institute Monoclonal antibodies against glycolipid antigens, methods of producing these antibodies, and use therefor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US6001634A (en) 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6887699B1 (en) 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
FR2664905B1 (fr) * 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
JP3037554B2 (ja) 1993-04-20 2000-04-24 寳酒造株式会社 免疫原性人工ポリペプチド
US6337070B1 (en) * 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
EP0621339B1 (en) 1992-09-17 2001-10-24 Takara Shuzo Co. Ltd. Immunogenic human influenza A virus haemagglutinin polypeptides
US5589174A (en) 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
GB9221654D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
US5674703A (en) 1992-12-02 1997-10-07 Woo; Savio L. C. Episomal vector systems and related methods
WO1994016109A1 (en) 1993-01-15 1994-07-21 Whitehead Institute For Biomedical Research Membrane fusion events and means for altering same
WO1994017826A1 (en) 1993-02-01 1994-08-18 Smithkline Beecham Corporation Vaccinal polypeptides
US5573916A (en) 1994-05-19 1996-11-12 Coretech, Inc. Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
AU712714B2 (en) 1994-10-03 1999-11-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule B7 gene in a recombinant virus expressing system
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DE69510207T3 (de) 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
AU727923B2 (en) 1995-09-27 2001-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of infectious respiratory syncytial virus from cloned nucleotide sequences
JP2820106B2 (ja) 1996-02-29 1998-11-05 日本電気株式会社 トラヒックシェーパ装置
US6261561B1 (en) 1996-04-19 2001-07-17 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens
WO1997040161A1 (en) * 1996-04-19 1997-10-30 Henry M. Jackson Foundation For The Advancement Of Military Medecine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
JP4413999B2 (ja) 1996-07-15 2010-02-10 アメリカ合衆国 クローニングされたヌクレオチド配列からの弱毒化呼吸シンシチウムウィルスワクチンの製造
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
KR20000048628A (ko) 1996-09-27 2000-07-25 윌리암 에이취 캘넌, 에곤 이 버그 모노네가비랄레스 목의 바이러스에서 감쇠를 책임지는 3' 게놈프로모터 영역 및 폴리머라제 유전자 돌연변이
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US5891705A (en) 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
US7227002B1 (en) 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
KR100702523B1 (ko) 1997-05-23 2007-04-04 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 클로닝된 뉴클레오타이드 서열로부터 약독화된파라인플루엔자 바이러스를 제조하는 방법
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
EP1012244B1 (en) 1997-07-11 2007-05-09 Yale University Rhabdoviruses with reengineered coats
WO1999015672A1 (en) 1997-09-19 1999-04-01 American Cyanamid Company Attenuated respiratory syncytial viruses
PT1098961E (pt) 1998-06-12 2008-04-23 Mount Sinai School Of Med Of T Vírus atenuados produzidos por engenharia genética indutores de interferão
EP1086207B1 (en) 1998-06-12 2007-01-17 Mount Sinai School Of Medicine Of The City University Of New York Novel methods and interferon deficient substrates for the propagation of viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
JP2003512812A (ja) 1998-12-23 2003-04-08 ボイス トンプソン インステイテュート フォア プラント リサーチ トランスジェニック植物における免疫原性ｂ型肝炎表面抗原の発現
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
CN1360634A (zh) 1999-04-29 2002-07-24 辛甄塔有限公司 抗除草剂植物
DE122008000056I1 (de) 1999-07-14 2009-04-09 Sinai School Medicine In vitro-rekonstitution von segmentierten negativstrang-rna-viren
IL148673A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Intranasal influenza virus vaccine
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US6770799B2 (en) 2000-03-17 2004-08-03 Thompson Boyce Plant Res Expression of recombinant human acetylcholinesterase in transgenic plants
SI1317559T1 (sl) 2000-04-28 2009-04-30 St Jude Childrens Res Hospital Sistem transfekcije dna za pripravo infektivne negativne verige virusne rna
US6632620B1 (en) 2000-06-22 2003-10-14 Andrew N. Makarovskiy Compositions for identification and isolation of stem cells
US7226774B2 (en) 2002-02-13 2007-06-05 Wisconsin Alumni Research Foundation Signal for packaging of influenza virus vectors
US20040091503A1 (en) * 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
US20070036809A1 (en) 2003-01-29 2007-02-15 Josef Michl Tolerance-induced targeted antibody production
US20050106178A1 (en) 2003-01-30 2005-05-19 Chiron Corporation Adjuvanted influenza vaccine
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
JP4368594B2 (ja) 2003-02-24 2009-11-18 株式会社インシリコサイエンス タンパク質構造予測装置、タンパク質構造予測方法、プログラム、および、記録媒体
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
NZ543348A (en) 2003-05-05 2008-08-29 Thompson Boyce Plant Res Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
DE60333042D1 (de) 2003-05-26 2010-07-29 Bartenschlager Ralf Eine aus dem genom von hepatitis-c-virus (hcv) genotyp 2a stammende nukleinsäure enthaltendes nukleinsäurekonstrukt und zelle mit dem dahinein transferierten nukleinsäurekonstrukt
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
PT2261376E (pt) 2003-11-04 2013-09-23 Univ Tulane Método para prevenir a fusão vírus:células inibindo a função da região de iniciação de fusão em vírus de rna tendo proteínas do invólucro fusogénicas de membrana de classe i
CA2568015C (en) * 2004-05-25 2013-08-27 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
ATE468390T1 (de) 2004-10-13 2010-06-15 Protalix Ltd System und verfahren zur produktion von antikörpern in der pflanzenzellkultur
WO2006104615A2 (en) 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
AU2006252406B2 (en) 2005-06-01 2012-05-17 California Institute Of Technology Method of targeted gene delivery using viral vectors
JP4758148B2 (ja) 2005-06-14 2011-08-24 泰三 宇田 インフルエンザウイルスのヘマグルチニンに対する抗体酵素
US7951384B2 (en) 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US20070064857A1 (en) 2005-08-19 2007-03-22 Winterberg Friedwardt M Thermonuclear plasma confinement with thermomagnetic currents generated by nuclear reactions from fusion neutrons
US8098789B2 (en) 2005-09-09 2012-01-17 Wisconsin Alumni Research Foundation Systems and methods for the cyclotron production of iodine-124
US8662363B2 (en) 2005-09-27 2014-03-04 Dennis Williams Golf car accessory
ATE539765T1 (de) 2005-11-04 2012-01-15 Novartis Vaccines & Diagnostic Grippeimpfstoffe mit kombinationen aus teilchenförmigen adjuvantien und immunverstärkern
EA016217B1 (ru) 2005-12-02 2012-03-30 Маунт Синай Скул Оф Медсин Химерные вирусы, представляющие неприродные поверхностные белки, и их применение
WO2007066334A1 (en) 2005-12-06 2007-06-14 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved influenza vaccine
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
CA2642054C (en) 2006-02-13 2017-11-21 Fraunhofer Usa, Inc. Influenza antigens, vaccine compositions, and related methods
US20070207171A1 (en) 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
EP2476432B1 (en) 2006-03-07 2015-08-19 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
EP2007765B1 (en) 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
US20100068223A1 (en) 2006-03-24 2010-03-18 Hanno Scheffczik Storage of Influenza Vaccines Without Refrigeration
US20070262178A1 (en) 2006-05-12 2007-11-15 Ultradent Products, Inc. Syringe delivery tip including an enlarged flocked wing element adjacent a distal delivery end
EP2522678A1 (en) 2006-05-15 2012-11-14 Sea Lane Biotechnologies, LLC Neutralizing antibodies to influenza viruses
US8148085B2 (en) * 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
DK2023952T3 (en) * 2006-05-18 2015-10-19 Epimmune Inc Induction of immune responses to influenza virus using polypeptide and nucleic acid compositions
EP2035565A4 (en) 2006-06-30 2010-07-21 Novavax Inc METHODS OF ENHANCING THE INCORPORATION OF PROTEINS IN VIRUS-LIKE PARTICLES (VLPs)
PL2048955T3 (pl) 2006-07-21 2013-11-29 California Inst Of Techn Nakierowane dostarczanie genu dla szczepienia komórek dendrytycznych
HRP20130163T1 (hr) 2006-09-07 2013-03-31 Crucell Holland B.V. Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba
EP2497495B3 (en) 2006-09-11 2021-02-17 Seqirus UK Limited Making influenza virus vaccines without using eggs
US20080075998A1 (en) 2006-09-22 2008-03-27 Tatsumi Ishihara Electrolyte membrane for electrochemical cell and a method of producing the same
US20080085876A1 (en) 2006-10-05 2008-04-10 Schwartz David L Insect sting treatment
CN103254308B (zh) 2007-06-15 2015-01-21 厦门大学 H5亚型禽流感病毒血凝素蛋白的单克隆抗体或其结合活性片段及其用途
EP2014279A1 (en) 2007-06-22 2009-01-14 Pevion Biotech AG Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof
DK2185191T3 (da) 2007-06-27 2012-12-03 Novartis Ag Influenzavacciner med lavt indhold af tilsætningsstoffer
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
US20090092635A1 (en) 2007-08-17 2009-04-09 Wyeth Heterologous prime-boost immunization regimen
US9421254B2 (en) 2007-09-24 2016-08-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunostimulatory combinations of TLR ligands and methods of use
FR2921387B1 (fr) * 2007-09-26 2012-04-20 Sanofi Pasteur Procede de production du virus de la grippe
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
NZ587108A (en) 2007-11-27 2013-04-26 Medicago Inc Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
WO2009079259A2 (en) 2007-12-06 2009-06-25 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
WO2009092038A1 (en) 2008-01-16 2009-07-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Influenza dna vaccination and methods of use thereof
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
CN102046656A (zh) 2008-03-28 2011-05-04 航道生物技术有限责任公司 针对病毒抗原的中和性分子
GB0905570D0 (en) 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
WO2010003766A2 (en) 2008-06-17 2010-01-14 Apogenix Gmbh Multimeric tnf receptors
EP2294202B1 (en) 2008-07-08 2015-05-20 Medicago Inc. Soluble recombinant influenza antigens
US20110177122A1 (en) 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
JP2012521786A (ja) * 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
CN102448986B (zh) 2009-05-11 2015-11-25 克鲁塞尔荷兰公司 能中和流感病毒h3n2的人结合分子及其应用
CA2800182A1 (en) 2009-05-26 2010-12-02 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
JP5871796B2 (ja) 2009-06-24 2016-03-01 メディカゴ インコーポレイテッド ヘマグルチニンを含むキメラインフルエンザウイルス様粒子
JP5845180B2 (ja) 2009-07-30 2016-01-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルス及びそれらの使用
JP5463107B2 (ja) 2009-09-14 2014-04-09 独立行政法人国立国際医療研究センター 新型インフルエンザを特異的に鑑別するモノクローナル抗体とそれを利用した免疫検出試薬
US20120219584A1 (en) 2009-10-05 2012-08-30 The United States Of America As Represented By The Secretary, Department Of Health Protection against pandemic and seasonal strains of influenza
JP2013060367A (ja) 2010-01-15 2013-04-04 Osaka Univ 抗インフルエンザ抗体及びインフルエンザ検出用デバイス
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
WO2011103453A2 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
EP2860190A3 (en) 2010-03-08 2015-07-15 Celltrion, Inc. Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
AU2011282423B2 (en) 2010-07-22 2015-05-14 Schrader, Sabariah Cross-protective pathogen protection, methods and compositions thereof
EP2758075B1 (en) 2011-09-20 2023-05-03 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
JP6294828B2 (ja) 2011-11-28 2018-03-14 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． インフルエンザウイルスワクチンおよびその使用
CA2894506C (en) 2012-12-11 2021-08-10 Vib Vzw Anti-influenza antibody
SG11201504728RA (en) 2012-12-18 2015-07-30 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
BR112015022623A2 (pt) 2013-03-14 2017-07-18 Contrafect Corp composição e métodos baseados em anticorpos neutralizantes, administrados por via intranasal para eficácia terapêutica melhorada
BR112016030577A8 (pt) 2014-07-10 2021-07-20 Janssen Vaccines & Prevention Bv polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, composição e usos destes
CN106661091B (zh) 2014-07-10 2020-10-30 扬森疫苗与预防公司 流行性感冒病毒疫苗及其用途

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN5012011722; ＧＥＲＨＡＲＤ　Ｗ: 'ＰＲＯＳＰＥＣＴＳ　ＦＯＲ　ＵＮＩＶＥＲＳＡＬ　ＩＮＦＬＵＥＮＺＡ　ＶＩＲＵＳ　ＶＡＣＣＩＮＥ' ＥＭＥＲＧＩＮＧ　ＩＮＦＥＣＴＩＯＵＳ　ＤＩＳＥＡＳＥＳ Ｖ１２　Ｎ４, 20060401, Ｐ５６９-５７４, ＥＩＤ *
JPN5012011723; ＨＯＲＶＡＴＨ　Ａ: 'Ａ　ＨＥＭＡＧＧＬＵＴＩＮＩＮ-ＢＡＳＥＤ　ＭＵＬＴＩＰＥＰＴＩＤＥ　ＣＯＮＳＴＲＵＣＴ　ＥＬＩＣＩＴＳ　ＥＮＨＡＮＣＥＤ　ＰＲＯＴＥＣＴＩＶＥ　以下備考' ＩＭＭＵＮＯＬＯＧＹ　ＬＥＴＴＥＲＳ Ｖ６０　Ｎ２／０３, 19980201, Ｐ１２７-１３６, ＥＬＳＥＶＩＥＲ　ＢＶ *
JPN5012011724; ＢＩＡＮＣＨＩ　ＥＬＩＳＡＢＥＴＴＡ: 'ＵＮＩＶＥＲＳＡＬ　ＩＮＦＬＵＥＮＺＡ　Ｂ　ＶＡＣＣＩＮＥ　ＢＡＳＥＤ　ＯＮ　ＴＨＥ　ＭＡＴＵＲＡＴＩＯＮＡＬ　ＣＬＥＡＶＡＧＥ　ＳＩＴＥ　ＯＦ　ＴＨＥ　ＨＥＭＡＧＧＬＵＴＩＮＩＮ　ＰＲＥＣＵＲＳＯＲ' ＪＯＵＲＮＡＬ　ＯＦ　ＶＩＲＯＬＯＧＹ Ｖ７９　Ｎ１２, 20050601, Ｐ７３８０-７３８８, ＴＨＥ　ＡＭＥＲＩＣＡＮ　ＳＯＣＩＥＴＹ　ＦＯＲ　ＭＩＣＲＯＢＩＯＬＯＧＹ *
JPN5012011725; ＭＯＫ　Ｈ: 'ＥＮＨＡＮＣＥＭＥＮＴ　ＯＦ　ＴＨＥ　ＣＤ８＋　Ｔ　ＣＥＬＬ　ＲＥＳＰＯＮＳＥ　ＴＯ　Ａ　ＳＵＢＤＯＭＩＮＡＮＴ　ＥＰＩＴＯＰＥ　ＯＦ　ＲＥＳＰＩＲＡＴＯＲＹ　以下備考' ＶＡＣＣＩＮＥ Ｖ２６　Ｎ３７, 20080902, Ｐ４７７５-４７８２, ＥＬＳＥＶＩＥＲ　ＬＴＤ *
JPN6014037659; Ｊ．　Ｇｅｎ．　Ｖｉｒｏｌ． ７７, 1996, ｐ．１４８３-１４８７ *
JPN6014037661; 感染・炎症・免疫 ２９　（２）, 1999, ｐ．１３１-１３３ *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016199557A (ja) * 2009-03-30 2016-12-01 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
JP2013526849A (ja) * 2010-03-30 2013-06-27 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
JP2016508133A (ja) * 2012-12-18 2016-03-17 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
US10583188B2 (en) 2012-12-18 2020-03-10 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US10544207B2 (en) 2013-03-14 2020-01-28 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
JP7357088B2 (ja) 2013-09-18 2023-10-05 レヴィセプト エルティーディー 融合タンパク質
JP2022068253A (ja) * 2013-09-18 2022-05-09 レヴィセプト エルティーディー 融合タンパク質
JP2020062011A (ja) * 2013-09-18 2020-04-23 レヴィセプト エルティーディーＬｅｖｉｃｅｐｔ Ｌｔｄ 融合タンパク質
JP2016531590A (ja) * 2013-09-18 2016-10-13 レヴィセプト エルティーディーＬｅｖｉｃｅｐｔ Ｌｔｄ 融合タンパク質
JP2017527303A (ja) * 2014-07-17 2017-09-21 レヴィセプト リミテッド Ｐ７５ｎｔｒニューロトロフィン結合タンパク質の治療的使用
JP7365378B2 (ja) 2014-07-17 2023-10-19 レヴィセプト リミテッド Ｐ７５ｎｔｒニューロトロフィン結合タンパク質の治療的使用
JP2021177766A (ja) * 2014-07-17 2021-11-18 レヴィセプト リミテッド Ｐ７５ｎｔｒニューロトロフィン結合タンパク質の治療的使用
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
JP6996756B2 (ja) 2016-05-19 2022-02-04 クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン がんの腫瘍崩壊療法のためのｖｓｖ／ｎｄｖハイブリッドウイルス
JP2019516374A (ja) * 2016-05-19 2019-06-20 クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン がんの腫瘍崩壊療法のためのｖｓｖ／ｎｄｖハイブリッドウイルス
US11266734B2 (en) 2016-06-15 2022-03-08 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
US11865173B2 (en) 2016-06-15 2024-01-09 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
US12233123B2 (en) 2016-06-15 2025-02-25 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
US12030928B2 (en) 2017-04-07 2024-07-09 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
JPWO2019124557A1 (ja) * 2017-12-21 2021-01-28 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
JP7382634B2 (ja) 2017-12-21 2023-11-17 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
US12364746B2 (en) 2018-06-21 2025-07-22 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
JP2023539771A (ja) * 2020-09-07 2023-09-19 インターベット インターナショナル ベー． フェー． Ｈａ抗体陽性ターゲットのためのｈａステムワクチン
WO2022071492A1 (ja) * 2020-09-30 2022-04-07 キリンホールディングス株式会社 インフルエンザウイルス抑制用の融合タンパク質およびこれを含む医薬組成物

Also Published As

Publication number Publication date
US20100297174A1 (en) 2010-11-25
JP2018134107A (ja) 2018-08-30
AU2010234849B2 (en) 2017-06-22
AU2017232138A1 (en) 2017-10-12
US20150297712A1 (en) 2015-10-22
AU2010234849A1 (en) 2011-11-17
JP2016199557A (ja) 2016-12-01
US9051359B2 (en) 2015-06-09
CA2787099A1 (en) 2010-10-14
US9849172B2 (en) 2017-12-26
EP3009145A1 (en) 2016-04-20
EP2413962A1 (en) 2012-02-08
WO2010117786A1 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
US10179806B2 (en) Influenza virus vaccines and uses thereof
US9849172B2 (en) Influenza virus vaccines and uses thereof
EP2536425B1 (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease
JP2022091775A (ja) インフルエンザウイルスワクチン及びその使用
US10736956B2 (en) Influenza virus vaccination regimens

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141127

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160209

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20160714